The purpose of the investigation was to assess positron emission tomography (PET), computed tomography (CT) and the image fusion of PET and CT (PET/CT) in the detection of metastases from gastrointestinal neuroendocrine tumors. In a prospective study, thirty-one patients were consecutively examined using a state-of-the-art PET/CT. PET was performed with a carbohydrated F-18-labeled somatostatin receptor ligand (Gluc-Lys([ 18 F]FP-TOCA) from the base of the skull to the proximal thigh using a Pico-3D PET scanner. CT was performed with a noncontrast low-dose CT (LD-CT) and a venous-dominant contrastenhanced CT (VD-CT) from the base of the skull to the proximal thigh and a hepatic arterialdominant contrast-enhanced CT (AD-CT) from the epigastric region using a 16-slice CT.
Introduction
Neuroendocrine tumors are slow-growing rare neoplasms of neuroectodermal origin that frequently express specific somatostatin receptors which can be of great value in the staging and treatment (1, 2) . The considerable heterogeneity are given in various classifications that differ in a number of criteria such as the localization of the primary tumor, tumor size, metastases, growth pattern, histomorphology, hormone production, silver affinity and immunohistochemical Seemann Technology in Cancer Research & Treatment, Volume 6, Number 3, June 2007 staining (3) (4) (5) . Primary neuroendocrine tumors are small neoplasms that arise predominantly in the gastrointestinal tract, pancreas, and lung. Theses tumors permit long-term survival, can be clinically symptom free for several years and metastases are frequently the first manifestation of the disease. The most common metastatic sites are the liver, lymph nodes, bone, lung, and peritoneal cavity. Hepatic metastases and the degree of liver involvement are considered major prognostic factors for survival (6) (7) (8) . Weber et al. (9) have reported that patients with an elevated number of liver metastases have a significantly worse 10-y survival rate (16%) compared to patients with limited metastatic liver disease (79%). Therefore, an early and accurate staging of hepatic disease is crucial, because complete resection is the only curative therapeutic approach (10). Bone metastases are frequently multiple at the time of detection; mostly in patients with liver metastases and indicate a poor prognosis (11). In an inoperable stage, treatment with somatostatin analogs is able to control hormone secretion and clinical symptoms in the majority of patients and, in some cases, is able to inhibit tumor growth (12).
Somatostatin receptor scintigraphy using radiolabeled analogs of somatostatin has become the standard in vivo imaging modality of choice in the identification and staging of neuroendocrine tumors and thus the most reliable tool for guiding therapy (13) (14) (15) (16) (17) (18) . The reported sensitivity for tumor detection with [ 111 In]DTPA-octreotide ranges from 60% to 90% and the specificity ranges from 85% to 98% (18-20) . Gluc-Lys([ 18 F]FP-TOCA PET allows a fast, high contrasting imaging of somatostatin receptor-positive tumors (21). Low lipophilicity, rapid renal tracer elimination, low liver uptake and intestinal activity, as well as fast and intense tumor accumulation were observed and provided excellent tumorto-nontumor ratios (21). Preliminary evaluation of Gluc-Lys([ 18 F]FP-TOCA showed promising results in an animal model and a single patient study (22) . The biokinetics and diagnostic performance of Gluc-Lys([ 18 F]FP-TOCA are superior to [ 111 In]DTPA-octreotide and -as far as can be derived from the literature -comparable with [ 68 Ga]-DOTA-DPhe 1 -Tyr 3 -octreotide ([ 68 Ga]DOTATOC) (21). CT is the standard morphological imaging modaliy for tumor staging and provide essential anatomical information. Radiological techniques allow precise localization of scintigraphic "hot spots" and discrimination of variable physiologic radiotracer uptake that can mimic metastatic lesions (23, 24) .
The objective of this prospective study was to investigate the diagnostic value of Gluc-Lys([ 18 F]FP-TOCA PET, low-dose CT (LD-CT), hepatic arterial-dominant contrast-enhanced CT (AD-CT), venous-dominant contrast-enhanced CT (VD-CT) and the image fusion of PET and CT (PET/LD-CT and PET/VD-CT) in the detection of metastases from gastrointestinal neuroendocrine tumors.
Materials and Methods

Study Patients
In a twelve-month period, thirty-one consecutive patients (23 men and 8 women) with metastatic disease of gastrointestinal neuroendocrine tumor were enrolled in this prospective study. PET/CT imaging was performed as pretherapeutic tumor staging of a targeted radiolabeled peptide therapy. Exclusion criteria were pregnancy, elevated serum creatinine levels >1.5 mg/dl, thyroid disease, allergic reactions to iodinated contrast agents and more than 50 liver lesions in a single imaging modality. In the medical history of the patients, the primary neuroendocrine tumor [small bowel (n=17), colon and rectum (n=11), appendix (n=2) and stomach (n=1)] had been surgically resected several years previously. Twenty patients had received treatment, including segmental hepatectomy (n=9), somatostatin analogs (n=12), systemic chemotherapy (n=9), interferon therapy (n=3), chemoembolization (n=1) and radiofrequency ablation (n=1) several months ago. All examinations were approved by the institutional ethics committee and the Federal Bureau of Radiation Protection (BfS). All patients granted informed consent. The mean age ± SD of the patients was 60.0 ± 10.3 years (range, 38 -83 years).
Imaging Techniques
Positron-emissions-tomography (PET) data were acquired with a high-count-rate lutetium oxyorthosilicate (LSO) detector Pico-3D full-ring PET scanner of a PET/CT (biograph Sensation 16 ® ; Siemens AG, Erlangen, Germany) from the base of the skull to the proximal thigh. As radiopharmaceutical, a glycosylated 18 F-labeled somatostatin analog (Gluc-Lys([ 18 F]FP-TOCA = N α -(1-deoxy-Dfructosyl)-N ε -(2-[ 18 F]fluoropropionyl)-Lys 0 -Tyr 3 -octreotate) was used. An activity of 148 ± 24 MBq (range, 100 -200 MBq) was intravenously injected 54.0 ± 6.5 minutes (range, 45 -70 minutes) before starting the measurements at a time point which has been proven to attain an optimal tumor-tobackground ratio (21). Depending on patient height, six to eight bed positions (4 minutes emission per bed position) with a 700-mm field of view (FOV) were measured. Images were reconstructed by means of an iterative procedure (4 iterations) with ordered subsets (8 subsets). The low-dose CT was used for the attenuation correction. Matrix size was 128 x 128.
Computed tomography (CT) data were acquired with the 16slice CT scanner of the PET/CT. For an optimal contrast of the gastrointestinal tract, 1,000-1,500 ml diluted diatrizoate meglumine (Gastrografin ® 1.5%, Schering AG, Berlin, Germany) was administered orally 30 minutes before starting the examination. An anterior-posterior scout-view was obtained for planning and determining the location of the scanning volume. First, a low-dose examination without contrast enhancement was performed from the base of the skull to the proximal thigh. Scanning parameters were 120 kV, 20 mAs, CARE Dose, 16 x 0.75-mm section collimation, 500-msec rotation time, and 15.0-mm table feed per rotation. After data acquisition of the PET, the contrast-enhanced examinations were performed. All patients received a total of 130 ml of a nonionic contrast agent (Imeron ® 300, Bracco ALTANA, Pharma GmbH, Konstanz, Germany) infused through an 18-gauge intravenous antecubital catheter according to the biphasic contrast-enhanced protocol (85 ml at a flow rate of 3 ml/sec and then 45 mL at 1.8 ml/sec) followed by a chaser bolus (30 ml saline with a flow rate of 1.8 ml/sec) by using a dual-head power injector (CT-injector missouri XD 2001 ® , Ulrich Medical Technic, Ulm, Germany). The hepatic arterial-dominant CT was acquired 35 seconds after the intravenous contrast media injection. The venousdominant contrast-enhanced CT was started 80 seconds after the intravenous contrast media injection from the base of the skull to the proximal thigh. Scanning parameters were 120 kV, 160 mAs, CARE Dose, 16 x 0.75-mm section collimation, 500-msec rotation time, and 15.0-mm table feed per rotation. All axial CT images were reconstructed using an increment of 1.5-mm with a 500 mm field of view (FOV) and a kernel of B30f medium smooth. Matrix size was 512 x 512.
The acquisition of PET emission data requires a relatively long time (few minutes) and represents an average of patient movement, and respiratory and cardiac motion. The acquisition of CT data is relatively short (few seconds) and therefore is performed using a breath-hold technique. To avoid a discrepancy in the average position of organs, a normal expiration technique during the CT data acquisition, where the patient stops respiration at the level of a normal expiration, was used to match the PET and CT images.
Image Interpretation
The examinations were analyzed on a lesion-by-lesion basis by an experienced specialist in radiology and nuclear medicine on a digital workstation (Viewing Software, Navigator, Siemens AG, Erlangen, Germany). The number, location, density and contrast enhancement of each highly suspicious metastatic lesion were described. For the evaluation of the PET images adapted standardized uptake values (SUVs) were used as threshold to increase lesion detectability because of the different physiological tracer uptake in the liver, spleen and pancreas, and the nonspecific tracer accumulation and excretion in the kidneys and the urinary tract (liver: SUV = 12.0; kidney: SUV = 17.0; spleen: SUV = 35.0; soft tissue, lymph nodes and bone: SUV = 5.0). Any focal tracer uptake higher than the choosen SUV for an organ was rated as a pathological tracer accumulation and classified as metastasis. For the evaluation of the CT images adapted windows (W) and centers (C) were used to increase lesion detectability [LD-CT (soft tissue: W = 200 and C = 50; lung parenchyma: W = 1400 and C = -700 and bone structures: W = 1400 and C = 400), AD-CT (soft tissue: W = 300 and C = 50) and VD-CT (soft tissue: W = 300 and C = 50; lung parenchyma: W = 1400 and C = -700 and bone structures: W = 1400 and C = 400)]. Lesions within parenchyma organs were rated as organ metastases if they were not clearly identified as certain benign lesions according to the standard CT criteria. Lymph nodes with a nodular shape and a diameter of more than 10 mm were staged as lymph node metastases. Pulmonary nodules were rated as metastasis if they were not clearly identified as benign (eg, pattern of calcification). The automatically fused PET/CT images (MSViewer ® , Navigator, Siemens AG, Erlangen, Germany) were analyzed on a lesion-by-lesion basis using the results from the single modalities. Lesions were rated as metastases if they were classified as malignant in at least one of the single imaging modalities.
Statistical Analysis
To assess a relative sensitivity of each imaging modality, the total number of metastases by summing the number of metastases depicted for each patient by the highest sensitive modality was used as reference standard and the ratio between the total number of metastases determined by each modality to the reference standard was calculated. The exact McNemar test using StatXact® 6 (Cytel Software Corporation, Cambridge, MA, USA) was used to assess the statistical significance in differences in the detection rate of liver, lymph node and osseous metastases for each imaging procedure. All p-values are two-sided. A global significance level of 0.05 was used. Multiple testing was considered using the Bonferroni approach.
Results
A total of 858 liver metastases in 31 patients were depicted, ranging from 2 to 45 mm in maximum diameter (median, 16 mm) using PET/VD-CT [Tab. 1]. For the detection of liver metastasis, PET/VD-CT (n=858; 100%) was significantly (P<0.001) superior to PET/LD-CT (n=785; 91.5%), PET (n= 779; 90.8%), VD-CT (n=634; 73.9%), AD-CT (n=390; 45.5%) and LD-CT (n=252; 29.4%) [ Fig. 1 ]. PET showed in 18 patients (58.1%) more liver lesions than VD-CT, VD-CT showed in 10 patients (32.2%) more liver lesions than PET and in 3 patients (9.7%) PET and VD-CT showed the same number of liver lesions. VD-CT showed in 28 patients (90.3%) more liver lesions than AD-CT and AD-CT showed in 3 patients (9.7%) more liver lesions than VD-CT. VD-CT showed in 28 patients (90.3%) more liver lesions than LD-CT, LD-CT showed in 2 patients (6.5%) more liver lesions than VD-CT and in 1 patient (3.2%) VD-CT and LD-CT showed the same number of liver lesions. AD-CT showed in 13 patients (41.9%) more liver lesions than LD-CT, LD-CT showed in 11 patients (35.5%) more liver lesions than AD-CT and in 7 patients (22.6%) AD-CT and LD-CT showed the same number of liver lesions. The liver lesions of all patients seen on LD-CT (n = 31; 100%) appeared hypodense. Using AD-CT, a hypervascular enhancement especially in the margin of the lesions in 27 patients (87.1%) and an inhomogeneous hypovascular enhancement in 4 patients (12.9%) was found. Using VD-CT, an inhomogenous hypovascular contrast enhancement in 15 patients (48.4%), a homogeneous hypovascular contrast enhancement in 14 patients (45.2%) and a peripheral enhancement of the margin in 2 patients (6.4%) was found.
Seemann
A total of 193 lymph node metastases in 22 patients (71.0%) were depicted, ranging from 4 to 36 mm in maximum diameter (median, 15 mm) using PET/VD-CT [Tab. 2]. For the detection of lymph node metastases, PET/VD-CT (n=193; 100%), was significantly (P<0.001) superior to PET/LD-CT (n=181; 93.8%), PET (n=181; 93.8%), VD-CT (n=125; 64.8%) and LD-CT (n=49; 25.4%) [ Fig. 2 ]. 68 lymph nodes (37.6%) (cervical n=1, mediastinal n=8, retroperitoneal n=28 and intraperitoneal n=31) showed a clearly increased tracer uptake in the PET but were smaller than 10 mm on VD-CT or could not be differentiated from small and large intestine. 12 lymph nodes (9.6%) (cervical n=1, mediastinal n=1, hilar n=1, retroperitoneal n=3 and intraperitoneal n=6) showed a size from 11 to 14 mm on VD-CT but no increased tracer uptake on PET.
A total of 567 osseous metastases in 22 patients (71.0%) were depicted, ranging from 4 to 18 mm in maximum diameter (median, 12 mm) using PET/ VD-CT [Tab. 3] . For the detection of osseous metastases, PET/VD-CT and PET/LD-CT (n=567; 100%) were significantly superior to PET (n=559; 98.6%) (P<0.005), VD-CT (n=231; 40.7%) (P<0.001) and LD-(n=231; 40.7%) (P<0.001) [ Fig. 3 ]. 14 of these patients (63.6%) showed metastases on LD-CT and VD-CT. 8 patients (36.4%) showed osseous metastases (336; 59.3%) on PET that could not be identified on CT images. Using CT, in 13 patients (92.9%) the metastases (n=115; 49.8%) were osteosclerotic or mixed osteosclerotic and osteolytic and in 1 patient (7.1%) the metastases (n=116; 50.2%) were primary osteolytic. In 1 patient without primary therapy 8 (21.1%) of the 38 mixed osteosclerotic and osteolytic osseous metastases showed no increased tracer uptake on PET.
Furthermore, using PET/VD-CT, PET/LD-CT, VD-CT and LD-CT a total of 9 intrapulmonal lesions, ranging from 4 to 14 mm in maximum diameter (median, 8 mm) in 3 patients (9.7%) were depicted, whereas PET (n=2; 22.2%) were less reliable. Peritoneal carcinomatosis was seen in 2 patients (6.5%) with all imaging modalities, but in 3 patients (9.7%) with VD-CT and PET/VD-CT. Two cardiac metastases were seen with PET, PET/LD-CT and PET/VD-CT and 2 metastases of the spleen were seen with VD-CT and PET/ VD-CT. Two cerebral metastases were seen on VD-CT, PET, PET/LD-CT and PET/VD-CT and a thyroidal metastasis with PET, PET/LD-CT and PET/VD-CT.
Discussion
In scientific literature, the fusion of molecular/metabolic and anatomic/morphologic information significantly improves the identification and characterization of malignancies, since these procedures complement one another to a nearly optimal degree (18, 25-28). PET can identify lesions beyond the diagnostic sensitivity of CT and allowed the proof of metastases at an earlier stage. However, CT also demonstrates metastases not found on PET. Therefore, an adequate diagnostic certainity for the detection of neuroendocrine tumors is not attained with any single imaging procedure. In this study, the combination of PET and venous-dominant contrast-enhanced CT (PET/VD-CT) revealed the highest detection rate for liver metastases, lymph node metastases, osseous metastases, intrapulmonal lesions, peritoneal carcinomatosis, cardiac metastases, metastases of the spleen, cerebral metastases and thyroidal metastasis and therefore formed the standard of reference. Nevertheless, an overall lesion-based sensitivity of 100% for metastases in the combination of PET and VD-CT is not a realistic value, because it is possible that individual metastases showed no octreotate accumulation and were not enlarged. The use of LD-CT for the image fusion with PET instead of a VD-CT leads to a loss in sensitivity in the detection of soft tissue and lymph node metastases but not in the detection of osseous metastases and intrapulmonal lesions.
Numerous studies have confirmed higher sensitivity, specificity, diagnostic accuracy and positive predictive value of somatostatin receptor scintigraphy (SRS) (90%, 80%, 83%, and 100%, respectively) compared with morphological imaging procedures (which have a sensitivity of between 50% and 70%, depending on the size and localization of the lesion) (14-18, 29). The sensitivity of SRS depend on the high variability in the expression of somatostatin receptors among the different tumor entities and even within different lesions in single patients (1, 30) , the limitations of the physical properties of SPECT imaging and finally the pharmacokinetic characteristics of Indium-111 DTPAoctreotide with high physiological uptake in liver and spleen and elimination by the kidney and at a low percentage by the hepatobiliary system. Tumors can be concealed due to a low target-to-background ratio and by the markedly bowel activity in the images. To reduce this limitations, the nuclear medicine imaging method with the highest resolution, the positron emissions tomography (PET) and a promising somatostatin receptor ligand, Gluc-Lys([ 18 F]FP-TOCA (N α -(1-deoxy-D-fructosyl)-N ε -(2-[ 18 F]fluoropropionyl)-Lys 0 -Tyr 3 -octreotate), was used. Gluc-Lys([ 18 F]FP-TOCA showed a very high affinity to human somatostatin receptor subtype (hsst) 2, a moderate affinity to hsst 4 and 5 and no affinity to hsst 1 and 3. Its low lipophilicity, low liver uptake, rapid renal elimination and low intestinal activity as well as its fast and high tumor accumulation provides excellent tumor-tobackground ratios (21, 22) .
The highest lesion-by-lesion based detection rate for liver metastases was found for PET/VD-CT. PET/LD-CT (91.5%) showed a lower detection rate, because of the lower sensitivity of LD-CT (29.4%) compared with VD-CT (73.9%). PET was the most sensitive single imaging procedure in the detection of liver metastases (90.8%). However, PET underestimated the extension of liver metastases or even missed the extension of the metastatic disease because of the low spatial resolution (6.3 x 6.3 x 6.0 mm 3 ), the physiological tracer uptake in the normal liver tissue and the dependency on the presence, type and density of the somatostatin receptors expressed by the tumor lesions as well as the tumor size (24, 31). Metastases with a low somatostatin receptor density and necrotic metastases revealed a low or no tracer uptake in the PET. Neuroendocrine liver metastases are usually highly vascularized with their blood supply arising from the hepatic artery. In theory, hepatic arterial phase images should therefore provide the best results in the detection of these metastases regardless of the imaging technique used (32). However, in some cases, venous phase imaging delineates the tumor best (33). Thus, commencing dual-phase imaging scanning following intravenous injection of contrast medium is recommended to optimize the sensitivity of the technique, both for the primary tumor and for the demonstration of liver metastases (34) (35) (36) . In agreement to our results, Paulson et al. (33) published the highest detection rate of neuroendocrine liver metastases for the venous-dominant phase (86.0%) followed by the hepatic arterial-dominant phase (83.2%) and the noncontrast phase (79.8%). However, the single imaging procedure CT underestimated in all phases the extension of liver metastases or even missed the extension of the metastatic disease, probably due to the low lesionto-liver contrast. LD-CT showed the lowest difference in density between the liver parenchym and the metastases.
In comparison to VD-CT, LD-CT detected 1% of additonal lesions, but not 22% as described by Oliver et al. (37) . In this study, the enhancement pattern of liver metastases in the AD-CT was typical peripheral hypervascular in 27 patients (87.1%) and atypical hypovascular in 4 patients (12.9%). In the literature, a typical hypervascular pattern of hepatic metastases from neuroendocrine tumors was described in 77-87% of 2%) and a peripheral enhanced rim in 2 patients (6.4%) was found. It is suggested that chemotherapy may alter the vascularity of metastases, thereby lowering the performance of enhanced hepatic arterial phase imaging (37). 9 of our patients (29.0%) had preciously received systemic chemotherapy. In these patients, the enhancement pattern of metastases was hypervascular in 7 patients (77.8%) and hypovascular in 2 patients (22.2%).
The highest lesion-by-lesion based detection rate for lymph node metastases was found for PET/VD-CT. PET/ LD-CT (93.8%) showed a lower detection rate, because of the lower sensitivity of LD-CT (25.4%) compared with VD-CT (64.8%). PET (93.8%) was the most sensitive single imaging procedure in the detection of lymph node metastases. The main advantage of lymph node staging with PET is the sensitive detection of serotonin-expressing small lymph nodes (<10 mm) which are not assessable with morphologic imaging leading to an improvement of the reference standard. However, unspecific focal tracer uptake of the small and large intestine can lead to false-positive findings. In agreement to our results, the assessment of the lymph node staging in neuroendocrine tumors is described as difficult and unsatisfactory using morphologic imaging procedures (4, 16, 39) . The weakness of morphologic lymph node staging is the known lack of reliable criteria, since assessment can be made only on the basis of size (40). On the one hand, lymph node metastases with a size smaller than 10 mm could not be detected but lymph nodes with a size of greater than 10 mm could also be caused by an inflammatory. Furthermore, the differentiation of abdominal lymph node metastases and small and large intestine without contrast media could be a problem using CT.
The highest lesion-by-lesion based detection rate for osseous metastases was found for PET/VD-CT and PET/LD-CT, because of the same sensitivity for VD-CT and LD-CT (40.7%). PET (98.6%) was the most sensitive single imaging procedure in the detection of osseous metastases. Using CT, the differentiation of degenerative changes of the vertebral column and osteosclerotic osseous metastases can be a problem. Similar to our results, Gibril et al. (41) published a typically osteosclerotic or mixed osteolytic and osteosclerotic pattern for bone metastases of endocrine tumors in 90% on standard radiography. Healing of metastases on treatment can lead to the formation of further sclerosis, which can be misdiagnosed as disease progression (41).
This study is limited because a detailed lesion-by-lesion based pathological analysis was not possible. Most of the patients had advanced metastatic disease and therefore, were not submitted to resection. However, primary disease of neuroendocrine tumor was proven in all patients.
Conclusions
For the best prognostic stratification and to guide the most appropriate therapeutic approach, the use of the most sensitive imaging procedure to detect metastases, evaluate the number of metastases and their distribution should be recommended.
The results from this study revealed that an adequate diagnostic certainity for the assessment of the extent of metastases of gastrointestinal neuroendocrine tumors is not attained with any single imaging procedure. The main advantage of PET is the identification of cancerous lesions beyond the diagnostic sensitivity of CT and therefore allowed the proof of malignancies at an earlier stage. However, CT is an excellent morphological imaging modality and demonstrates metastases not found on PET. Whole-body PET/VD-CT is a very valuable diagnostic modality for oncological imaging and is superior to the single imaging modalities and PET/LD-CT. The problem of false negative PET results can not be solved by PET/LD-CT.
